QINGDAO,
China, Feb. 18, 2025 /PRNewswire/ -- Akso Health
Group (NASDAQ: AHG) (hereinafter referred to as "Akso Health," "the
Company," or "we") announced today its integration of DeepSeek's
advanced artificial intelligence technology. This initiative aims
to further enhance AI-powered medical consultation, optimize
healthcare resource allocation, and provide users with more precise
and efficient medical services. The utilization of DeepSeek
not only represents a significant breakthrough in the field of
AI-driven healthcare but also sets a new benchmark for the
industry's intelligent transformation.
As an innovative medical technology company, AHG
leverages DeepSeek's multimodal large-scale models, deep
learning frameworks, and big data processing capabilities to
upgrade its AI-powered diagnosis system. The upgraded system will
integrate patient text descriptions, medical imaging, and
laboratory test results, utilizing NLP and deep learning to provide
more accurate diagnoses and personalized treatment recommendations.
Additionally, DeepSeek's model training framework
helps AHG refine its AI models, enhancing diagnostic accuracy
and response speed.
Furthermore, AHG will utilize DeepSeek to develop an AI-powered
medical assistant to support doctors in retrieving patient records,
analyzing similar cases, and recommending treatment plans, aiming
to significantly improve diagnostic efficiency. AHG also
incorporates human-centric AI interactions, ensuring a more natural
and empathetic user experience, reducing patient anxiety, and
optimizing the overall consultation experience.
Ms. Yilin (Linda) Wang , CEO of
AHG stated, "The utilization of DeepSeek is a major milestone in AI
powered healthcare. By leveraging DeepSeek's technological
expertise, we aim to enhance diagnostic accuracy and deliver
superior healthcare services to users worldwide."
Looking ahead, AHG will continue to explore AI applications in
research and development, health management, and telemedicine,
driving the healthcare industry toward a smarter and more efficient
future.
About Akso Health Group
Akso Health Group (NASDAQ: AHG), formerly known as Xiaobai
Maimai Inc., upon exploration of e-commerce platforms, the Company
started exploring the healthcare equipment and product trading and
related healthcare services business. Currently we specialize in
the sales of medical devices in China and in the
United States and also conduct certain radiotherapy oncology
centers in the U.S. From March 2024, the Company indirectly
acquired the equity interests of Tianjin Deyihui
Internet Hospital Co., Ltd and Tianjin Deyihui
Clinic Co., Ltd. which provides online medical consultations for
initial diagnosis, follow-up consultations, and management of
chronic diseases.
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements are made under the "safe
harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These statements can be identified by terminology such
as "will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates," "potential," "continue," "ongoing,"
"targets," "guidance" and similar statements. The Company may also
make written or oral forward-looking statements in its periodic
reports to the U.S. Securities and Exchange Commission (the "SEC"),
in its annual report to shareholders, in press releases and other
written materials and in oral statements made by its officers,
directors or employees to third parties. Any statements that are
not historical facts, including statements about the Company's
beliefs and expectations, are forward-looking statements that
involve factors, risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking
statements. Such factors and risks include, but not limited to the
following: risks related to our ability to obtain equipment,
technology, license and talents at satisfactory terms to grow the
medical equipment business and/or to start the planned healthcare
business, if at all; risks regarding the effect of the COVID-19
pandemic on the Company and the Company's position in a
post-COVID-19 environment; risks related to the Company's ability
to adapt and make the necessary adjustments to compete and operate
effectively; risks related to decisions or changes in governmental
policies in the healthcare segment; risks related to increased
competition and the development of new competing services; the risk
that we may be unable to develop or achieve commercial success for
our medical and healthcare services in a timely manner, or at all;
risks related to regulatory requirements or enforcement in relevant
jurisdiction and changes in the structure of the healthcare system
or healthcare payment systems; risks related to our ability to
successfully integrate and derive benefits from any technologies
that we license or acquire; risks related to our projections about
our business, results of operations and financial condition; and
risks related to the potential market opportunity for our products
and services. Further information regarding these and other risks,
uncertainties or factors is included in the Company's filings with
the SEC. All information provided in this announcement is current
as of the date of this announcement, and the Company does not
undertake any obligation to update such information, except as
required under applicable law.
For more information, please
visit http://www.ahgtop.com/en/index.html
For investor inquiries, please contact:
Akso Health Group
Investor Relations
Email: ir@ahgtop.com
View original
content:https://www.prnewswire.com/news-releases/ahg-utilizes-deepseek-to-advance-ai-in-healthcare-302378879.html
SOURCE Akso Health Group
